Rovafovir etalafenamide

Rovafovir etalafenamide (GS-9131), a proagent of the adenosine nucleotide analogue GS-9148, is an orally active nucleoside reverse transcriptase inhibitor (NRTI) . Rovafovir etalafenamide is potent and active against a variety of NRTI mutants, and shows potent anti-HIV-1 activity[1][2].

Product Specifications

CAS Number

[912809-27-9]

Product Name Alternative

GS-9131

UNSPSC

12352005

Target

HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rovafovir-etalafenamide.html

Purity

99.85

Solubility

10 mM in DMSO

Smiles

FC([C@](O1)([H])N2C3=NC=NC(N)=C3N=C2)=C[C@H]1OC[P@](OC4=CC=CC=C4)(N[C@@H](C)C(OCC)=O)=O

Molecular Formula

C21H24FN6O6P

Molecular Weight

506.42

References & Citations

[1]Mackman RL, et al. Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. Bioorg Med Chem. 2010;18 (10) :3606‐3617.|[2]Rai MA, Pannek S, Fichtenbaum CJ. Emerging reverse transcriptase inhibitors for HIV-1 infection. Expert Opin Emerg Drugs. 2018;23 (2) :149‐157.|[3]Cihlar T, et al. Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob Agents Chemother. 2008;52 (2) :655‐665.